InvestorsHub Logo
Followers 20
Posts 1059
Boards Moderated 0
Alias Born 04/01/2013

Re: isaeed post# 10836

Thursday, 07/18/2013 3:44:45 PM

Thursday, July 18, 2013 3:44:45 PM

Post# of 426289
I'm not sure it's big news in regards to near term sales, I think the biggest thing it does is give more credence to Anchor on time approval.

However, Anchor is a slam dunk as it gets so not really sure that's much of a question. The fact they can use the JELIS study results at all with FDA approval is interesting though.

Since most of Anchor Will be geared toward PCP's and they have been through cardiologists several times perhaps this will help them as they start expanding to PCP's on a wider level. It is also good to have several months to see how the JELIS study plays with doctors, will give them some help on how to sell the Anchor indication as they get some time to learn what works well and what doesn't.

I think the Pfizer news is more interesting but since that was not presented as strongly it is kind of glossed over as pure rumor. They need a BP partner, Pfizer they have relationships with and makes the most sense in that way, good to hear they may have interest in being the partner. A BP partner with a fair deal and the stock is over 10 right away and header for over 15 and would mean large Anchor sales in year 1 of Anchor.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News